Increased Risk of Brain Tumors Linked to Certain Progestogen Hormone Medications

Thursday - May 9 2024, 16:57 UTC - 9 months ago

A recent study found that prolonged use of certain progestogen hormone medications was linked to an increased risk of brain tumors. The study highlights the need for further research on the risks associated with these medications and the importance of careful consideration by healthcare providers.

The use of certain progestogen hormone medications may come with an increased risk of brain tumors, according to a recent study published in The BMJ. The research, conducted in France, looked at the association between progestogens and intracranial meningioma, a type of brain tumor. Progestogens are synthetic hormones that are often used to treat gynecological conditions, menopause symptoms, and as contraception. While some factors that contribute to an increased risk of meningiomas, such as age and sex, have been identified, the risks associated with specific progestogens have not been well studied. The aim of this study was to evaluate these risks and better inform patients and healthcare providers.

The study analyzed data from over 18,000 women in France who had undergone surgery for intracranial meningioma between 2009 and 2018. Each case was compared to five women without meningioma, matched by age and location. The progestogens examined in this study included progesterone, hydroxyprogesterone, dydrogesterone, medrogestone, medroxyprogesterone acetate, promegestone, dienogest, and levonorgestrel intrauterine systems. The results showed that prolonged use (one year or more) of medrogestone, medroxyprogesterone acetate injection, and promegestone were associated with significantly increased risks of brain tumors. However, no increased risk was observed for progesterone or hormonal intrauterine systems, regardless of the dose of levonorgestrel they contained. The examination of other progestogens, like hydroxyprogesterone and dienogest, was inconclusive due to the small sample sizes of exposed individuals.

While the study did not establish direct cause and effect, the findings raise concerns about the potential risks of certain progestogens. The researchers call for further studies to better understand the risks associated with these medications and inform patients of potential adverse effects. It is important for healthcare providers to carefully consider the risks and benefits of using progestogens and to monitor patients closely for any concerning symptoms.